CorePlus has long been recognized as a trailblazer in the field of medical innovation, consistently delivering groundbreaking solutions that redefine healthcare standards. With bladder cancer ranking as the 10th cancer-related death cause in the U.S., per the American Cancer Society, this effort with AIxURO could not be timelier. This cutting-edge addition to CorePlus’s portfolio of precision diagnostic tools underscores the company’s commitment to addressing critical health challenges through advanced technology, ultimately, improving patient outcomes and saving lives.
“This achievement represents the culmination of over two years of dedicated collaboration and innovation. Through persistence and precision, our teams have developed and integrated an AI algorithm that meets the highest standards for clinical use. CorePlus continues to advance its mission of transforming patient care through precision pathology, turning years of research into real life impact for patients,” said Mariano de Socarraz, Founder & CEO of CorePlus. Together with AIxMed, we have refined every aspect of the process to ensure clinical precision and reproducibility at scale. The AIxURO™ Urine Cytology Algorithm embodies the rigorous standards we envisioned and uphold at CorePlus, he added.